Literature DB >> 25040256

Clinical and genetic characteristics of a large monocentric series of patients affected by thyroid hormone (Th) resistance and suggestions for differential diagnosis in patients without mutation of Th receptor β.

Enrico Macchia1, Martina Lombardi, Valentina Raffaelli, Paolo Piaggi, Lorenzo Macchia, Ilaria Scattina, Enio Martino.   

Abstract

OBJECTIVE: The syndrome of resistance to thyroid hormone (RTH) is caused by a mutation of TH receptor β (TRβ) in 80% of cases. Patients without mutation (non-TR-RTH) may have a biochemical pattern that is difficult to differentiate from that of pituitary TSH-secreting adenoma (TSHoma). Herein, we report a large monocentric series of RTH focusing on patients with non-TR-RTH, to evaluate possible clinical or biochemical parameters able to distinguish them from TSHoma. DESIGN AND PATIENTS: We retrospectively reviewed the data of 99 consecutive patients with inappropriate TSH secretion (IST) syndrome referred to our Department between 1983 and 2011, identifying 68 patients with RTH and 31 patients with TSHomas. MEASUREMENTS: Patient records were reviewed for the main clinical, biochemical and imaging characteristics.
RESULTS: Of our 68 patients with RTH, 16 (23·5%) did not show a TRβ mutation and did not have affected family members. Of these 16 patients, three developed a TSHoma, during follow-up. To distinguish non-TR-RTH from TSHoma, we identified appropriate cut-off values for the main biochemical parameters that demonstrated the greatest sensitivity and specificity (T3 suppression test, α-subunit/TSH molar ratio, α-subunit assay and TRH test) and we calculated the probability for each patient to develop a TSHoma.
CONCLUSIONS: The application of the identified cut-offs could become a very useful tool in the challenging differential diagnosis between sporadic non-TR-RTH and TSHoma. It would then be possible to select the patients at higher risk of developing a TSHoma and therefore needing a closer follow-up.
© 2014 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25040256     DOI: 10.1111/cen.12556

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  7 in total

Review 1.  Mutational Landscape of Resistance to Thyroid Hormone Beta (RTHβ).

Authors:  Paola Concolino; Alessandra Costella; Rosa Maria Paragliola
Journal:  Mol Diagn Ther       Date:  2019-06       Impact factor: 4.074

2.  Thyroid hormone resistance from newborns to adults: a Spanish experience.

Authors:  A Vela; G Pérez-Nanclares; I Ríos; I Rica; N Portillo; L Castaño
Journal:  J Endocrinol Invest       Date:  2019-02-01       Impact factor: 4.256

Review 3.  Thyrotropin-secreting pituitary adenomas: epidemiology, diagnosis, and management.

Authors:  Fatemeh G Amlashi; Nicholas A Tritos
Journal:  Endocrine       Date:  2016-01-21       Impact factor: 3.633

4.  Secondary Hyperthyroidism due to an Ectopic Thyrotropin-Secreting Neuroendocrine Pituitary Tumor: A Case Report.

Authors:  Christian Trummer; Hannes Reiher; Verena Theiler-Schwetz; Marlene Pandis; Christian Gstettner; Peter Potzinger; Tilman Keck; Thomas R Pieber; Sigurd Lax; Johannes Haybaeck; Vinzenz Stepan; Stefan Pilz
Journal:  Eur Thyroid J       Date:  2020-01-21

5.  Thyroid hormone resistance and the value of genetics: Three case reports.

Authors:  Xiao Xiao; Chen Lv; Tianxiao Zhu; Huiling Chen
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

Review 6.  Resistance to Thyroid Hormone Beta: A Focused Review.

Authors:  Theodora Pappa; Samuel Refetoff
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-31       Impact factor: 5.555

7.  The Differential Diagnosis of Discrepant Thyroid Function Tests: Insistent Pitfalls and Updated Flow-Chart Based on a Long-Standing Experience.

Authors:  Irene Campi; Danila Covelli; Carla Moran; Laura Fugazzola; Chiara Cacciatore; Fabio Orlandi; Gabriella Gallone; Krishna Chatterjee; Paolo Beck-Peccoz; Luca Persani
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-07       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.